Skip to main content

Table 2 Cox proportional hazards analyses of the association between PFS and the predicted level of resistance to the considered drugs in the merged IDRC and LLMPP cohort

From: Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models

  Univariate (N = 690) Multivariate (N = 604)
  HR (95% CI) P-value HR (95% CI) P-value
REGS classifier     
CHO 2.33 (1.64,3.30) 2.05e-06 2.30 (1.57,3.37) 1.78e-05
Cyclophosphamide (C) 0.95 (0.70,1.30) 0.764 0.99 (0.71,1.37) 0.949
Doxorubicin (H) 2.52 (1.77,3.59) 2.81e-07 2.55 (1.74,3.72) 1.29e-06
Vincristine (O) 2.07 (1.48,2.88) 2.04e-05 1.69 (1.19,2.40) 0.003
REGS predictor     
CHO 1.22 (1.09,1.36) 0.000353 1.22 (1.09,1.37) 0.0009
Cyclophosphamide (C) 0.97 (0.92,1.02) 0.184 0.98 (0.93,1.03) 0.438
Doxorubicin (H) 1.10 (1.05,1.16) 5.53e-05 1.10 (1.04,1.16) 0.0005
Vincristine (O) 1.67 (1.38,2.01) 9.3e-08 1.59 (1.30,1.93) 4.79e-06
  1. In the multivariate analysis the Cox proportional hazards regression is adjusted for IPI. The estimated HR’s for the REGS classifiers compare patients classified as resistant to patients classified as sensitive. In contrast, the estimated HR’s for the REGS predictors are based on an increase of 10 in the predicted AUC 0 .